相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Musa Yilmaz et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML
Jorge E. Cortes et al.
BLOOD (2018)
Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD-mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.
Mark J. Levis et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
R. Swords et al.
LEUKEMIA (2012)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
